Actelion Gains Rights to Auxilium’s Xiaflex® in Canada, Australia, Brazil and Mexico
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 3 (Table of Contents)
Published: 6 Mar-2012
DOI: 10.3833/pdr.v2012.i3.1692 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Actelion Pharmaceuticals has gained the rights to develop and commercialise Auxilium Pharmaceuticals’ Xiaflex® (collagenase clostridium histolyticum), a first-in-class biologic for Dupuytren’s contracture (DC) and Peyronie’s disease (PD), in Canada, Australia, Brazil and Mexico in a deal worth up to US$68...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS